



**SDI Review Form 1.6**

Journal Name:	<a href="#">Journal of Complementary and Alternative Medical Research</a>
Manuscript Number:	Ms_JOCAMR_47917
Title of the Manuscript:	Evaluation of in vivo Synergistic Hypoglycemic & Hypolipidemic Activity of Ethanolic Extract of Calotropis gigantean Leaves in Combination to Metformin in Alloxan Induced Rats
Type of the Article	

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ol style="list-style-type: none"> <li>1. The content of the introduction is insufficient to establish where the frontier of knowledge is with the studied plant. There is no detailed information on chemistry and pharmacology.</li> <li>2. In the methodology lack details of the feeding type of the animals, the units of measurement need to be reviewed, there are no reference of the doses administered, there is no manuscript approval of the ethics committee and there is no information about euthanasia. The extract was also not lyophilized.</li> <li>3. In the results, the tables must be adequate. those of the manuscript are pictures.</li> <li>4. There is no discussion of the results with the chemical compounds of the plant.</li> </ol>	<ol style="list-style-type: none"> <li>1. Phytochemistry, traditional use as well as pharmacological use are mentioned already in paper. The discussion on the rationale of the study with target plant for hypoglycemic &amp; hypolipidemic activity has been included in detail.</li> <li>2. The extract was ready to use so lyophilisation was not needed. Feeding type (oral /I.P) already mentioned. There is institutional ethical committee that approved the progression &amp; successful ending of animal handling.</li> <li>3. Corrected</li> <li>4. Why should I have to discussion of chemical compounds? Already mentioned the probable presence of chemicals responsible for hypoglycemic &amp; hypolipidemic activity.</li> </ol>
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments		

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	(If yes, Kindly please write down the ethical issues here in details)	Antidiabetic & hypoglycemic test were sarried out on rat model in strict compliance with the National Research council guidelines on the care and use of laboratory animals to minimize research animal pain and suffering